Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence

A Zambelli; E Gallerani; O Garrone; R Pedersini; E Rota Caremoli; P Sagrada; E Sala; M E Cazzaniga

doi:10.1016/j.critrevonc.2023.104104

Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence

Crit Rev Oncol Hematol. 2023 Nov:191:104104. doi: 10.1016/j.critrevonc.2023.104104. Epub 2023 Sep 1.

Authors

A Zambelli¹, E Gallerani², O Garrone³, R Pedersini⁴, E Rota Caremoli⁵, P Sagrada⁶, E Sala⁷, M E Cazzaniga⁸

Affiliations

¹ Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
² Ospedale di Circolo di Varese, Varese, Italy.
³ Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
⁴ ASST Spedali Civili, Brescia, Italy.
⁵ Medical Oncology, Ospedale di Bergamo, Bergamo, Italy.
⁶ Onco-Hematology Unit, ASST Lodi, Lodi, Italy.
⁷ Oncology Unit, ASST Monza Ospedale San Gerardo, Monza, Italy.
⁸ School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy; Phase 1 Research Unit, Fondazione IRCCS san Gerardo dei Tintori, Monza, Italy. Electronic address: marina.cazzaniga@unimib.it.

PMID: 37659765
DOI: 10.1016/j.critrevonc.2023.104104

Abstract

Hormone-receptor positive (HR+), Human-Epidermal-growth Factor negative (HER2-) breast cancer, including the Luminal A and the Luminal B subtypes, is the most common in women diagnosed with early-stage BC. Despite the advances in screening, surgery and therapies, recurrence still occurs. Therefore, it is important to identify early those factors that significantly impact the recurrence risk. Based on current evidence and their professional expertise, a Panel of oncologists discussed the definition of high risk of recurrence in early breast cancer. Histological grade, nodal involvement, genomic score, histological grade, tumor size, and Ki-67 proliferation index were rated as the most important factors to define the high risk in patients with early breast cancer. All these factors should be considered comprehensively to tailor the choice of treatment to the peculiar characteristics of each patient.

Keywords: Early breast cancer; HR+; Luminal; Risk of recurrence.

Publication types

Review